Liyun Y. Miao

No. 321 Zhongshan Road
Nanjing, 210008, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 79 publications

Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.

Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.

Journal: The New England journal of medicine

Published: July 08, 2026

An exploratory ImmunoScore based on early on-treatment changes in NLR and LDH in small-cell lung cancer receiving first-line chemoimmunotherapy.

An exploratory ImmunoScore based on early on-treatment changes in NLR and LDH in small-cell lung cancer receiving first-line chemoimmunotherapy.

Journal: Future oncology (London, England)

Published: June 06, 2026

International Consensus on Severe Lung Cancer-The Second Edition.

International Consensus on Severe Lung Cancer-The Second Edition.

Journal: Translational lung cancer research

Published: March 21, 2026

Expert consensus on the detection and clinical application of tumor mutational burden.

Expert consensus on the detection and clinical application of tumor mutational burden.

Journal: Cancer biology & medicine

Published: February 18, 2026

Artificial intelligence in lung cancer: from diagnosis to therapy.

Artificial intelligence in lung cancer: from diagnosis to therapy.

Journal: Current opinion in oncology

Published: November 12, 2025

Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.

Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.

Journal: The New England journal of medicine

Published: October 17, 2025

Advances in the application of tumor vaccines and combination strategies: new perspectives in lung cancer treatment.

Advances in the application of tumor vaccines and combination strategies: new perspectives in lung cancer treatment.

Journal: Frontiers in immunology

Published: September 17, 2025

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.

Journal: Signal transduction and targeted therapy

Published: August 25, 2025

International guidelines on the diagnosis and treatment of NUT carcinoma.

International guidelines on the diagnosis and treatment of NUT carcinoma.

Journal: Innovation (Cambridge (Mass.))

Published: April 11, 2025

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.

Journal: Cancer biology & medicine

Published: April 09, 2025

One-year mortality risk prediction model for patients with interstitial lung disease and lung cancer.

One-year mortality risk prediction model for patients with interstitial lung disease and lung cancer.

Journal: Translational lung cancer research

Published: March 02, 2025

Expert consensus on cancer treatment-related lung injury.

Expert consensus on cancer treatment-related lung injury.

Journal: Journal of thoracic disease

Published: February 12, 2025

Showing 1-12 of 79

Last Updated: 09/26/2026